Literature DB >> 11476436

Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia.

M M Zeylemaker1, C A Jaspers, M G van Kraaij, M R Visser, I M Hoepelman.   

Abstract

The optimal duration of treatment for catheter-related Staphylococcus aureus bacteremia is not known. Short courses (< or = 2 weeks) of therapy should be viewed with caution because essential data on late complications, such as osteomyelitis and metastatic abscesses, are lacking. This study represents a retrospective analysis of the data from 49 adult patients hospitalised in the period 1994-1996 (mean age, 57 years; range, 20-90 years; 47% male) and from whom Staphylococcus aureus was cultured concomitantly from peripheral blood and catheter segments. Forty-six venous catheters, two arterial catheters, and one unknown type of catheter were used. Forty-four patients were treated with effective anti-Staphylococcus aureus antibiotics. Twenty patients had a favourable outcome, defined as no complication and no death during 1 year of follow-up, 24 patients had complications, 14 patients died due to attributable mortality, and 5 other patients died of an underlying disease without showing signs or symptoms of a complication. Patients were categorised according to the duration of treatment. There were small differences between a shorter (1-14 days) and a longer (>14 days) course of antibiotics with regard to favourable outcome (41% vs. 33%), complications (48% vs. 53%), attributable death (31% vs. 20%), and death due to underlying disease (41% vs. 33%), respectively. The rates of complications and death were high, but a definite conclusion cannot be drawn because the study was underpowered. More randomised trials are needed, but, until the results of such trials are available, the duration of therapy should not be shortened to less than 14 days.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11476436     DOI: 10.1007/pl00011278

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  4 in total

1.  Staphylococcus aureus: The persistent pathogen.

Authors:  B Lynn Johnston; John M Conly
Journal:  Can J Infect Dis       Date:  2003-11

2.  Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.

Authors:  Yong Pil Chong; Song Mi Moon; Kyung-Mi Bang; Hyun Jung Park; So-Youn Park; Mi-Na Kim; Ki-Ho Park; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

3.  Duration of antibiotic therapy for Staphylococcus aureus bacteraemia: the long and the short of it.

Authors:  E M Eichenberger; V G Fowler; T L Holland
Journal:  Clin Microbiol Infect       Date:  2020-01-20       Impact factor: 13.310

4.  Management of Staphylococcus aureus bacteraemia (SAB) in the oncology patient: Further evidence supports prompt removal of central venous catheters and shorter duration of intravenous antimicrobial therapy.

Authors:  Colum P Dunne; Phelim Ryan; Roisin Connolly; Suzanne S Dunne; Mohammed A Kaballo; James Powell; Bernie Woulfe; Nuala H O'Connell; Rajnish K Gupta
Journal:  Infect Prev Pract       Date:  2020-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.